Miami Cancer Institute, a part of Baptist Health South Florida, is a state-of-the-art center that serves as the primary destination for patients from the Southeast U.S., the Caribbean, and Latin America. 

The center is one of a few centers in the world capable of providing all the latest available radiation therapy technologies, and it started treating patients in January 2017.

When it was time to determine a treatment planning system that would encompass the various delivery platforms, including proton therapy, RayStation became a natural choice.

The $430 million, 395,000-square-foot Miami Cancer Institute (MCI) offers their patients access to almost all radiation delivery technologies commercially available and does it all under one roof.

MCI currently treats with IBA Proteus PLUS proton therapy, ViewRay MRIdian MR Linac, Gamma Knife Icon Radiosurgery, CyberKnife, Radixact TomoTherapy, True Beam, brachytherapy and radionuclide therapy.

“The idea was that we want to use the best available technology to provide the most optimal care, and the building was designed to house all these different technologies to accomplish this," said Craig McKenzie, director of medical dosimetry at MCI.

"By having every technological tool in the toolbox, one can better evaluate and customize the best treatment plan for every patient,” said McKenzie.

“Other centers might have all the technology available to them, but in different locations. We can customize our patient’s treatment to be mono-technology-based or perhaps capitalize on dosimetric advantages of using multiple technologies to deliver patients the best possible plan. That is unique,” said Alonso N. Gutiérrez, chief physicist at MCI.  

The First Selection of RayStation

For this world-class center, the choice of the treatment planning system (TPS) was essential. The selection of RayStation as sole TPS for the proton therapy at MCI “was a natural choice,” according to Gutiérrez.

“RayStation is a clear market leader within proton therapy. Proton therapy is evolving fast and so is RaySearch, catering to their customers’ needs with large development teams that can implement changes fast. The time from development, until we can use new features clinically, has shortened,” he continued.

RayStation’s functionality and speed were key factors in the decision to choose RayStation, said McKenzie. “RayStation gives us the best results in planning and evaluation, and does it fast,” he stated.

Gutiérrez also points out that RayStation’s ability to support many different delivery systems was an important part of the selection, for future implementation at the clinic.

“We are interested in using RayStation as the premier choice for all technologies in the future, moving toward a single TPS,” he said. As of now, the center primarily uses RayStation for proton planning but will start using it for photon and TomoTherapy planning.

“We are currently in training for the photon, and we already use some of the tools available to us. For example, we do our evaluation comparisons in RayStation. We are actively working on using RayStation to plan for TomoTherapy, and our goal is to treat a patient by the end of October,” Gutiérrez said.